Teva Pharmaceuticals announced the launch of Rizatriptan Benzoate Tablets, the generic of Merck‘s Maxalt. Maxalt is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine with or without aura.
Maxalt is presumed to exert its therapeutic effects in the treatment of migraine headache by binding to the receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Rizatriptan Benzoate Tablets are available in 5mg and 10mg strengths as 6×3 blister packs.
For more information call (888) TEVA-USA or visit www.tevagenerics.com.